Soleus Capital Management’s Pacira BioSciences PCRX Stock Holding History

Soleus Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-22,250	Closed	-$1.7M	–	81
2022 Q1	$1.7M	Sell	22,250 -79,350	-78%	-$5.29M	0.22%	57
2021 Q4	$6.11M	Buy	101,600 +35,600	+54%	+$1.96M	0.61%	35
2021 Q3	$3.7M	Buy	+66,000	New	+$3.8M	0.58%	43
2020 Q4	–	Sell	-10,200	Closed	-$613K	–	76
2020 Q3	$613K	Sell	10,200 -2,000	-16%	-$116K	0.32%	53
2020 Q2	$640K	Buy	12,200 +5,200	+74%	+$217K	0.36%	50
2020 Q1	$235K	Buy	+7,000	New	+$291K	0.27%	41

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Soleus Capital Management's PCRX Position: Q2 2022 in Review

Soleus Capital Management sold out of Pacira BioSciences (PCRX) in Q2 2022, closing a stake of 22,250 shares — an estimated $1.7M sold.

Soleus Capital Management first reported a position in PCRX in Q1 2020 and held it in 6 quarters. The position peaked at $6.11M in Q4 2021. 284 funds tracked by Wall St. Rank hold PCRX as of Q2 2022.

Soleus Capital Management reported no remaining Pacira BioSciences position as of Q2 2022 after selling out during the quarter.
Soleus Capital Management sold 22,250 Pacira BioSciences shares in Q2 2022, an estimated $1.7M.
Soleus Capital Management first reported a position in Pacira BioSciences in Q1 2020 and held it in 6 quarters.
Soleus Capital Management's Pacira BioSciences position peaked at $6.11M in Q4 2021.
284 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2022.

Based on Soleus Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.